These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19622585)

  • 41. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice.
    Sun L; Zhang Q; Luan H; Zhan Z; Wang C; Sun B
    J Exp Clin Cancer Res; 2011 Mar; 30(1):30. PubMed ID: 21414214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
    Song SG; Kim S; Koh J; Yim J; Han B; Kim YA; Jeon YK; Chung DH
    Cancer Immunol Immunother; 2021 Jul; 70(7):2035-2048. PubMed ID: 33420630
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation.
    Nunez MI; Behrens C; Woods DM; Lin H; Suraokar M; Kadara H; Hofstetter W; Kalhor N; Lee JJ; Franklin W; Stewart DJ; Wistuba II
    J Thorac Oncol; 2012 May; 7(5):833-40. PubMed ID: 22729036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
    Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comprehensive epidermal growth factor receptor gene analysis from cytological specimens of non-small-cell lung cancers.
    Savic S; Tapia C; Grilli B; Rufle A; Bihl MP; de Vito Barascud A; Herzog M; Terracciano L; Baty F; Bubendorf L
    Br J Cancer; 2008 Jan; 98(1):154-60. PubMed ID: 18087280
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidermal Growth Factor Receptor Gene Mutation Status in Primary Lung Adenocarcinoma and Corresponding Bone Metastases.
    Shi PX; Li YT; Wang SY; Sun RZ; Xu HT; Dong QZ; Zhao Y; Wang EH; Liu Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):49-56. PubMed ID: 30601156
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
    Fujimoto N; Wislez M; Zhang J; Iwanaga K; Dackor J; Hanna AE; Kalyankrishna S; Cody DD; Price RE; Sato M; Shay JW; Minna JD; Peyton M; Tang X; Massarelli E; Herbst R; Threadgill DW; Wistuba II; Kurie JM
    Cancer Res; 2005 Dec; 65(24):11478-85. PubMed ID: 16357156
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.
    Saad AG; Yeap BY; Thunnissen FB; Pinkus GS; Pinkus JL; Loda M; Sugarbaker DJ; Johnson BE; Chirieac LR
    Cancer; 2008 Oct; 113(8):2129-38. PubMed ID: 18720359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
    Daniele L; Macrì L; Schena M; Dongiovanni D; Bonello L; Armando E; Ciuffreda L; Bertetto O; Bussolati G; Sapino A
    Mol Cancer Ther; 2007 Apr; 6(4):1223-9. PubMed ID: 17406029
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases.
    Wei Q; Chen L; Sheng L; Nordgren H; Wester K; Carlsson J
    Int J Oncol; 2007 Sep; 31(3):493-9. PubMed ID: 17671674
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
    Kalikaki A; Koutsopoulos A; Trypaki M; Souglakos J; Stathopoulos E; Georgoulias V; Mavroudis D; Voutsina A
    Br J Cancer; 2008 Sep; 99(6):923-9. PubMed ID: 19238633
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.
    Sihto H; Lundin J; Lundin M; Lehtimäki T; Ristimäki A; Holli K; Sailas L; Kataja V; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
    Breast Cancer Res; 2011 Sep; 13(5):R87. PubMed ID: 21914172
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LDA-SVM-based EGFR mutation model for NSCLC brain metastases: an observational study.
    Hu N; Wang G; Wu YH; Chen SF; Liu GD; Chen C; Wang D; He ZS; Yang XQ; He Y; Xiao HL; Huang DD; Xiong KL; Wu Y; Huang M; Yang ZZ
    Medicine (Baltimore); 2015 Feb; 94(5):e375. PubMed ID: 25654374
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
    Magnuson WJ; Lester-Coll NH; Wu AJ; Yang TJ; Lockney NA; Gerber NK; Beal K; Amini A; Patil T; Kavanagh BD; Camidge DR; Braunstein SE; Boreta LC; Balasubramanian SK; Ahluwalia MS; Rana NG; Attia A; Gettinger SN; Contessa JN; Yu JB; Chiang VL
    J Clin Oncol; 2017 Apr; 35(10):1070-1077. PubMed ID: 28113019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.